No abstract

No abstract

No abstract

Monitoring of MMF trough levels may play a role in the management of cardiac transplant recipients during the first year post transplant.

Background:  Chronic use of corticosteroids (CS) following transplantation is associated with significant long‐term morbidities. Minimizing exposure to CS to improve long‐term outcomes, without compromising allograft function, remains an important goal in transplantation. Objectives:  This single‐center, prospective, randomized, open‐label study was designed to evaluate the efficacy of Thymoglobulin® as part of a CS‐sparing regimen in cardiac transplantation. Methods:  Thirty‐two low‐risk cardiac transplant patients were randomized in a 1:1 ratio to receive either a Thymoglobulin‐based CS‐avoidance regimen (CS‐avoidance group; n = 16) or a long‐term CS‐based regimen with no antibody induction (control group; n = 16). Pulse CS therapy was used for the treatment of acute cellular rejection in both groups. Results:  Baseline characteristics were similar between groups. At one yr, there was no significant difference in the mean incidence of acute cellular rejection (≥3A) episodes between the CS‐avoidance and control groups, 0.81 ± 1.05 and 1.07 ± 1.03, respectively. Importantly, the CS‐avoidance patients had significant improvement in muscle strength and less bone loss compared with the control patients during the first six months post‐transplant. Conclusions:  CS‐avoidance regimen with Thymoglobulin induction appeared to be safe and effective in cardiac transplantation. Further studies are required to demonstrate the long‐term safety and benefits of such a regimen.